摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-[3-(1-adamantyl)-4-methoxycarbonylethylphenyl]-2-naphthoic acid | 139611-85-1

中文名称
——
中文别名
——
英文名称
6-[3-(1-adamantyl)-4-methoxycarbonylethylphenyl]-2-naphthoic acid
英文别名
6-[3-(1-Adamantyl)-4-(3-methoxy-3-oxopropyl)phenyl]naphthalene-2-carboxylic acid
6-[3-(1-adamantyl)-4-methoxycarbonylethylphenyl]-2-naphthoic acid化学式
CAS
139611-85-1
化学式
C31H32O4
mdl
——
分子量
468.593
InChiKey
HTEHBBNKAVMPKM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    7.8
  • 重原子数:
    35
  • 可旋转键数:
    7
  • 环数:
    7.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    63.6
  • 氢给体数:
    1
  • 氢受体数:
    4

文献信息

  • Composition pharmaceutique ou cosmétique contenant en association un rétinoîde et un stérol
    申请人:CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA
    公开号:EP0465343B1
    公开(公告)日:1994-06-15
  • NOUVEAUX COMPOSES POLYCYCLIQUES AROMATIQUES ET LEUR UTILISATION EN MEDECINE HUMAINE OU VETERINAIRE ET EN COSMETIQUE
    申请人:CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA)
    公开号:EP0584191B1
    公开(公告)日:1997-08-13
  • CaM Kinase II Inhibitor Improves Retinoic Acid Therapy and Inhibits the Proliferation of Myeloid Leukemia Cells
    申请人:Collins Steven J.
    公开号:US20080255244A1
    公开(公告)日:2008-10-16
    A method of treating a cancer (e.g., myeloid leukemia) in a subject in need thereof, is carried out by administering the subject a CaM kinase II (CaMK II) inhibitor. In some embodiments, the CaMK II inhibitor is administered concurrently with a retinoid. In some embodiments, the CaMK II inhibitor is CaMK II gamma inhibitor. Compositions and formulations useful for carrying out such methods are also described.
  • USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN
    申请人:Fabius Biotechnology
    公开号:US20210338558A1
    公开(公告)日:2021-11-04
    The present invention addresses the need for an improved delivery system that is able to specifically target the skin for improved bioavailability and minimization of side effects resulting from administration of the active ingredient or ingredients. One aspect of the present invention is a targeting composition comprising: (1) a skin care agent or an agent that is a cosmeceutical agent; (2) an intermediate release linker bound to the skin care agent or cosmeceutical agent; (3) a targeting moiety bound to the intermediate release linker, the targeting moiety for binding the targeting composition to native collagen fibers; and (4) optionally, a carrier component to enhance delivery to the skin. The present invention also describes methods of use of these targeting compositions.
  • US5547983A
    申请人:——
    公开号:US5547983A
    公开(公告)日:1996-08-20
查看更多